ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2687

Prevalence of Abortions and Fetal Atrioventricular Block in Patients with Positive ANTI-RO and ANTI-La Antibodies

Isabel Martinez Cordellat1, Francisco Miguel Ortiz-Sanjuán1, Jose Ivorra Cortes1, Luis Gonzalez Puig1, Inmaculada Chalmeta Verdejo1, Irene Calabuig Sais2, Elena Grau Garcia1,3, Carlos Feced Olmos1, Eztizen Labrador Sanchez1, Karla Arevalo Ruales1, Rosa Negueroles Albuixech1, Jorge Fragio Gil1, Jose Luis Valero Sanz1, Cristina Alcañiz Escandell1,3, Carmen Najera Herranz1, Gema Poveda Marin1,3 and Jose Andres Roman Ivorra1,2,3, 1Department of Rheumatology, Hospital Universitario y Politecnico La Fe, Valencia, Spain, 2Universidad Católica de Valencia, Valencia, Spain, 3IIS La Fe, Valencia, Spain

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Antibodies

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Sjögren's Syndrome - Poster II: Clinical Science

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:   Anti-SSA/Ro and anti-SSB/La antibodies are present in inflammatory autoimmune disease patient sera, and there are related to different clinical manifestations. It is well known the association between the presence of these antibodies in maternal blood and fetal atrioventricular block. However, there are no much studies about infertility or repeated abortions and anti-SSA/Ro and anti-SSB/La antibodies in broad series. The aim of this study is to characterise a cohort of patients with positive anti-SSA/Ro and/or anti-SSB/La antibodies and to evaluate the prevalence of abortions and neonatal mortality.

Methods:   Observational descriptive study with 162 patients older than 15 years old with pregnancies history and positive anti-SSA/Ro and/or anti-SSB/La antibodies from February 2011 to July 2015. We consider healthy women with pregnancies history and with comparable characteristics as negative control group.  

Results:   We included 162 patients with positive anti-SSA/Ro and/or anti-SSB/La antibodies with a mean age of 50.5±14.2 years old. Main diagnosis were systemic lupus erythematosus (n=85), Sjögren syndrome (n=40), rheumatoid arthritis (n=16), systemic sclerosis (n=6), mixed connective tissue disease (n=3) and other diagnosis (n=12). Lupus anticoagulant was positive in 8 cases and 57 patients showed low complement values. 37% of patients had at least one pregnancy, and the 36.7% aborted during pregnancy. There were no significant differences in the abortion incidence between our cohort of patients and the healthy control group considered. We observed 4 cases of fetal atrioventricular block, all of them with positive anti-SSA/Ro and/or anti-SSB/La antibodies and only in one case also with positive lupus anticoagulant.

Conclusion:   In our series, pregnant women with positive anti-SSA/Ro and/or anti-SSB/La antibodies did not show high prevalence of abortion. However, the positivity of these antibodies was statistically correlated with the presence of fetal atrioventricular block.


Disclosure: I. Martinez Cordellat, None; F. M. Ortiz-Sanjuán, None; J. Ivorra Cortes, None; L. Gonzalez Puig, None; I. Chalmeta Verdejo, None; I. Calabuig Sais, None; E. Grau Garcia, None; C. Feced Olmos, None; E. Labrador Sanchez, None; K. Arevalo Ruales, None; R. Negueroles Albuixech, None; J. Fragio Gil, None; J. L. Valero Sanz, None; C. Alcañiz Escandell, None; C. Najera Herranz, None; G. Poveda Marin, None; J. A. Roman Ivorra, None.

To cite this abstract in AMA style:

Martinez Cordellat I, Ortiz-Sanjuán FM, Ivorra Cortes J, Gonzalez Puig L, Chalmeta Verdejo I, Calabuig Sais I, Grau Garcia E, Feced Olmos C, Labrador Sanchez E, Arevalo Ruales K, Negueroles Albuixech R, Fragio Gil J, Valero Sanz JL, Alcañiz Escandell C, Najera Herranz C, Poveda Marin G, Roman Ivorra JA. Prevalence of Abortions and Fetal Atrioventricular Block in Patients with Positive ANTI-RO and ANTI-La Antibodies [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/prevalence-of-abortions-and-fetal-atrioventricular-block-in-patients-with-positive-anti-ro-and-anti-la-antibodies/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-abortions-and-fetal-atrioventricular-block-in-patients-with-positive-anti-ro-and-anti-la-antibodies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology